Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), today announced financial results for the third quarter of 2014.
Third Quarter Results and Balance Sheet Highlights
At September 30, 2014, cash and cash equivalents were $17,773,680 compared to $15,696,243 at December 31, 2013. The increase of approximately $2.1 million was due primarily to $4.3 million cash received from warrant and stock option exercises and $7.5 million net proceeds from the sale of our common stock in the nine months ended September 30, 2014, offset by $9.7 million of operating cash expenses.
Help employers find you! Check out all the jobs and post your resume.
Third Quarter Results and Balance Sheet Highlights
At September 30, 2014, cash and cash equivalents were $17,773,680 compared to $15,696,243 at December 31, 2013. The increase of approximately $2.1 million was due primarily to $4.3 million cash received from warrant and stock option exercises and $7.5 million net proceeds from the sale of our common stock in the nine months ended September 30, 2014, offset by $9.7 million of operating cash expenses.
Help employers find you! Check out all the jobs and post your resume.
